$CARSGEN-B(02171)$ Honestly, the value of CARsgen doesn’t rely on BD deals to be justified. CT041 targets gastric cancer，a major indication in China, not some niche disease like overseas players focus on. Just look at their recent double-blind trial: 2:1 randomization, and yet 40% of the control group eventually crossed over to receive CT041.

If it weren’t widely acknowledged by doctors and patients as the best available treatment, would that even happen? My view hasn’t changed，CT041 is the most promising CAR-T for solid tumors worldwide, period. The current valuation of CARsgen? Way below what it should be. Their universal product 0596 already saw 6 CRs out of 7, and the rest of the pipeline? Basically being given away for free.